Know Cancer

or
forgot password

Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy


Phase 2
13 Years
N/A
Not Enrolling
Both
Membranous Glomerulonephritis

Thank you

Trial Information

Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy


This is a phase 2 trial to evaluate the safety and effectiveness of a new immunosuppressive
drug, sirolimus, in patients with idiopathic and lupus membranous nephropathy. Patients
(age greater than or equal to 13 years) will be invited to participate if they have
persistent nephritic range proteinuria despite standard treatment with an angiotensin
converting enzyme inhibitor or an angiotensin receptor blocker for at least one month,
unless intolerant. These individuals are at risk for renal function deterioration as well
as cardiovascular and thrombo-embolic complications of the nephrotic syndrome. Renal
function, the degree of proteinuria and side effects will be monitored closely throughout
the study. Physiologic measures of glomerular function will be examined at study entry and
at the conclusion of the trial.

Inclusion Criteria


- INCLUSION CRITERIA:

Ability and willingness to provide informed consent (adults greater than or equal to 18
years) or assent (children greater than or equal to 13 years) to all aspects of the study
after full information is provided.

Nephrotic range proteinuria that persists for at least 3 months.

Nephrotic range proteinuria that persists despite angiotensin antagonist therapy (ACE
inhibitor or ARB) for at least on month, unless intolerant. If patients have not started
ACE inhibitor therapy before they are referred to NIH, we plan to start lisinopril 5 mg
daily. We will advance the dose of ACE inhibitor as tolerated. Nephrotic range
proteinuria, defined as 24 hour urine protein excretion greater than or equal to 3.5 g/d,
must be documented in at least two 24 hour urine collections obtained during the month
prior to initiating sirolimus. Incomplete urine collections (based on inadequate
creatinine excretion) will be excluded.

Renal biopsy must reveal typical changes of membranous nephropathy by light and electron
microscopy.

SLE as defined by the presence of at least 4 criteria established by the American
Rheumatism Association (Lupus Membranous Nephropathy) or no evidence of a secondary form
of membranous nephropathy (Idiopathic Membranous Nephropathy).

EXCLUSION CRITERIA:

Intolerance to sirolimus or prior use of sirolimus for membranous nephropathy.

Estimated GFR less than 30 mL/min/1.73(2) (determined by the 5 variable version of the
MDRD Study prediction equation).

Immunosuppressive medications or experimental medications of any type during the two-month
period prior to initiating sirolimus, with the following two exceptions:

First, patients with lupus membranous nephropathy are permitted to have received modest
doses of corticosteroids (no more than the equivalent of prednisone 10mg/day) for control
of extra-renal manifestations of SLE during the two-month period prior to starting
sirolimus treatment.

Second, patients with worsening nephrotic syndrome (urine protein excretion rate doubles
+/or serum albumin decreases by greater than or equal to 1.0 g/ dL to less than 2.5 g/dL
on at least 2 determinations during or following a previous immunosuppressive treatment)
should fulfill the following criteria:

a) should be off prednisone for at least 2 weeks before performing the baseline evaluation
and starting sirolimus (if the patient has idiopathic membranous nephropathy): b) should
be on low-dose corticosteroids (no more than the equivalent of prednisone 10 mg/day) for
at least 2 weeks before performing the baseline evaluation and starting sirolimus (if the
patient lupus membranous nephropathy); c) should be off cyclosporine for at least 2 weeks
before performing the baseline evaluation and starting sirolimus; d) should be off
cyclophosphamide, chlorambucil, azathioprine and mycophenolate mofetil for at least 4
weeks before performing the baseline evaluation and starting sirolimus;

Children less than 13.0 years.

Active acute or chronic infection requiring antimicrobial therapy or serious viral
infection (e.g. HIV, hepatitis, herpes zoster). Patients with a reactive PPD must have
completed a 6 to 12 month course of isoniazid as recommended by an infectious disease
consultant. Patients with a non-reactive PPD and non-reactive anergy panel must complete
a 6 to 12 month course of isoniazid if recommended by an infectious disease consultant.

Pregnant women, nursing mothers or individuals (men and women) not practicing birth
control.

Uncontrolled hypertension, defined as BP greater than 140/90 on greater than 25% of
measurements. Blood pressures will be measured 3 times at each clinic visit after the
patient has sat quietly for at least 5 minutes. Thus at least 6 BP determinations will be
recorded prior to initiating sirolimus therapy.

Chronic liver disease sufficiently severe to impair sirolimus metabolism; this would
include prolonged pro-thrombin time. Patients with abnormal liver function tests will be
evaluated by the Hepatology Consult Service to determine whether protocol participation is
appropriate.

Basal thrombocytopenia less than 100,000 cells/microliters or absolute neutrophil count
less than 2000 cells/microliters or hematocrit less than 30.

Cancer diagnosis or cancer recurrence within the preceding 5 years, excluding basal cell
carcinoma of the skin.

Routine use of NSAIDS, defined as NSAID use more than two doses a week.

Clinically significant medical conditions, which in the opinion of the investigators,
could increase the subject's risk of participating in the study or could confound the
interpretation of the results of the study.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The number of patients who are in 1) complete remission or 2) complete or partial remission.

Outcome Time Frame:

12 months after starting sirolimus

Safety Issue:

No

Principal Investigator

Howard A Austin, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Authority:

United States: Federal Government

Study ID:

030071

NCT ID:

NCT00050713

Start Date:

December 2002

Completion Date:

August 2007

Related Keywords:

  • Membranous Glomerulonephritis
  • Kidney Disease
  • Glomerulonephritis
  • Lupus Nephritis
  • Nephrotic Syndrome
  • Hyperlipidemia
  • Glomerulonephritis
  • Glomerulonephritis, Membranous
  • Kidney Diseases

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892